lung cancer Archives

VisionGate protocol shows promise, pulmonologists say

VisionGate

Two recent surveys conducted by an independent, third-party research group validated the market demand for VisionGate’s LuCED test as well as its recently licensed drug therapy, Iloprost, in the diagnosis and treatment of patients at risk of lung cancer. LuCED, represented as “Product X” in surveys among 100 pulmonologists, is a non-invasive test to aid… Read More →

VisionGate gets investment from Trinnovate Ventures

VisionGate

Trinnovate Ventures today announced it will partner with Phoenix-based VisionGate to help accelerate clinical trial programs for both LuCED, a non-invasive diagnostic test targeting early stage lung cancer that responds best to therapy, and Iloprost, a chemoprevention drug for patients who have a pre-cancerous condition of the lungs called dysplasia.  Trinnovate Ventures, a subsidiary of… Read More →

VisionGate acquires exclusive rights to Iloprost

cancer

VisionGate, Inc., a biotech company in the early lung cancer detection space, announced, Thursday, it acquired exclusive rights to the University of Colorado’s patent for the use of the drug Iloprost in the prevention of lung cancer. This makes VisionGate one of the first companies to evolve from a diagnostic company to a diagnostic and… Read More →

Renowned surgeon joins VisionGate advisory board

VisionGate

VisionGate, Inc. a company that has developed a non-invasive test for the early detection of lung cancer, LuCED, announced that nationally renowned thoracic surgeon Dr. Harvey Pass has joined its Medical Advisory Board. Dr. Pass specializes in detecting, diagnosing and treating pleural mesothelioma and lung cancer. He is also a renowned cancer researcher widely known… Read More →

Dignity Health in Arizona invests in VisionGate

VisionGate

VisionGate has received financial backing from Dignity Health in Arizona for development of a revolutionary, non-invasive test for the early detection of lung cancer, the world’s deadliest cancer. Patient sputum samples are processed on the company’s patented Cell-CT® system – aptly named because it takes an optical CT scan of individual cells to generate digital,… Read More →

TGen finds clue to stop spread of lung cancer

cancer

Two cell surface receptors might be responsible for the most common form of lung cancer spreading to other parts of the body, according to a study led by the Translational Genomics Research Institute (TGen). The hepatocyte growth factor receptor (HGFR/MET) and fibroblast growth factor-inducible 14 (FN14) are proteins associated with the potential spread of non-small… Read More →

TGen identifies key lung cancer enabler

cancer

Researchers at the Translational Genomics Research Institute (TGen) have discovered a protein, Mcl-1, that helps enable one of the most common and deadly types of cancer to survive radiation and drug treatments. Non-small cell lung cancer (NSCLC) makes up about 85 percent of the nearly 160,000 Americans expected to die this year from lung cancer,… Read More →